STERIS (STE) Stock Forecast & Price Target

STERIS
Bull Case

Here are some ways that investors could benefit from investing in STERIS plc:

• STERIS plc recently reported first-quarter fiscal 2027 earnings on August 5, 2026, where it beat analyst consensus estimates by reporting an EPS of $2.59 against an expected $2.49, demonstrating strong operational performance and profitability with a net margin of 13.34%.
• The company has a strong institutional backing, with Wellington Management Group LLP increasing its holdings by 21.9% in the second quarter and Public Employees Retirement System of Ohio acquiring a new stake of 54,849 shares valued at approximately $11.55 million, indicating confidence from major financial institutions.
• STERIS plc is currently trading at $229.37, which is below the average analyst price target of $278.00, suggesting potential upside for investors as the stock is valued at a 28.04 P/E ratio, which is reasonable given the company's growth trajectory and recent dividend increase to $0.69 per quarter.
• The company is investing $600 million in a new chemistry manufacturing, research, and distribution complex in North Carolina, which is expected to boost capacity and efficiency, supporting long-term growth and operational excellence in the healthcare and life sciences sectors.
• STERIS plc has a solid financial position with a debt-to-equity ratio of 0.23 and a current ratio of 1.91, indicating a strong balance sheet and liquidity, which provides a buffer against economic uncertainties and supports the company's ability to invest in growth opportunities.